Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 3/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674855 | 0.92 | GABRA1 (0.35) | PPARGPPARAGABRA1GABRB2CXCR4 | |
| SCHEMBL16374660 | 0.88 | CXCR4 (0.33) | PPARGPPARACXCR4RXRANR1H2 | |
| SCHEMBL2834770 | 0.88 | TBXAS1 (0.31) | CXCR4RXRANR1H2NR1H3 | |
| SCHEMBL14701619 | 0.87 | PPARG (0.34) | PPARGPPARAGABRA1GABRB2CXCR4 | |
| SCHEMBL14674925 | 0.82 | FOLH1 (0.34) | — | |
| SCHEMBL16374705 | 0.80 | FPR2 (0.35) | CXCR4RXRANR1H2NR1H3BCHE | |
| SCHEMBL2832286 | 0.79 | FPR2 (0.35) | CXCR4 | |
| SCHEMBL15197282 | 0.78 | FPR2 (0.35) | — | |
| SCHEMBL15199007 | 0.77 | CA1 (0.44) | TSHR | |
| Bicarbonate SCHEMBL17685157 | 0.76 | FPR2 (0.33) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505192-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505192-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2739316-B1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARM INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2739316-B1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARM INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2739316-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013022797-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | PPARG 2719/4885PPARA 3441/4885GABRA1 3233/4885 |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA2 | PPARG 2445/4885PPARA 3087/4885GABRA1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.